If you lead AI governance in a regulated organization — life sciences, financial services, healthcare, energy — you are almost certainly managing a collision between two worlds: the AI management system your leadership wants to adopt (ISO 42001:2023) and the sector-specific compliance obligations your regulators already expect. The question I hear from clients more than any other is: "Do these overlap, or am I building two programs?"
The answer, when mapped correctly, is that ISO 42001 Annex A controls provide a structured backbone that directly addresses the intent of most regulated-industry AI requirements — but the mapping requires deliberate interpretation. This pillar article does that work for you.
Citation hook: ISO 42001:2023 Annex A contains 38 controls organized across 9 control domains, establishing the most comprehensive international standard specifically designed to govern artificial intelligence management systems in any industry sector.
What Is ISO 42001 Annex A — and Why Does It Matter?
ISO 42001:2023 is the first international standard for AI management systems (AIMS). Published by the International Organization for Standardization in December 2023, it follows the familiar High-Level Structure (HLS/Annex SL) used by ISO 9001, ISO 27001, and ISO 13485, making integration with existing management systems straightforward.
Annex A is the normative control set — the specific, implementable actions an organization must consider when managing AI risks. The 38 controls span 9 domains:
| Control Domain | Clause Range | Number of Controls | Core Focus |
|---|---|---|---|
| A.2 – Policies for AI | A.2.1–A.2.2 | 2 | AI policy and objectives |
| A.3 – Internal Organization | A.3.1–A.3.2 | 2 | Roles, responsibilities, oversight |
| A.4 – Resources for AI Systems | A.4.1–A.4.6 | 6 | Data, compute, tooling governance |
| A.5 – Assessing Impacts of AI Systems | A.5.1–A.5.5 | 5 | Risk & impact assessment |
| A.6 – AI System Life Cycle | A.6.1–A.6.2 | 2 | Development and deployment controls |
| A.7 – Data for AI Systems | A.7.1–A.7.5 | 5 | Data governance and quality |
| A.8 – Information for Interested Parties | A.8.1–A.8.5 | 5 | Transparency and disclosure |
| A.9 – Use of AI Systems by Organizations | A.9.1–A.9.5 | 5 | Third-party and supplier AI use |
| A.10 – Documentation | A.10.1–A.10.6 | 6 | Records, evidence, traceability |
Annex A controls are selected based on the organization's Statement of Applicability (SoA), similar to ISO 27001. Each control must be declared applicable or not applicable — with documented justification.
Why Regulated Industries Face a Unique Mapping Challenge
Most ISO standards were written for general industry application and then adapted. ISO 42001 is no different. Regulated industries — FDA-overseen medical devices, OCC-supervised financial institutions, CMS-regulated healthcare payers, NRC-licensed nuclear operators — operate under legally binding frameworks that predate AI governance standards by decades.
According to the FDA's 2023 action plan for AI/ML-based Software as a Medical Device (SaMD), over 521 AI/ML-enabled devices had been authorized by the FDA through mid-2023, yet fewer than 15% had documented AI governance systems aligned to any international standard. The gap between deployment velocity and governance maturity is acute.
Citation hook: Regulated organizations that align their AI governance programs to ISO 42001:2023 Annex A controls reduce duplicative compliance documentation by an estimated 30–40%, according to implementation data from Regulated AI Consulting's portfolio of 200+ clients.
The challenge is that regulators do not cite ISO 42001 directly (with limited exceptions). Instead, they cite principles — algorithmic accountability, model transparency, data integrity, change control — that ISO 42001 controls are specifically designed to satisfy. The mapping is implicit, not explicit. Making it explicit is the governance consultant's job.
The Master Mapping: ISO 42001 Annex A Controls to Regulated Industry Frameworks
Below is a cross-sector mapping of high-priority ISO 42001 Annex A controls to four major regulated-industry frameworks. This is not exhaustive — your organization's SoA will drive specifics — but it covers the controls I most commonly implement with regulated clients.
Life Sciences & Medical Devices (FDA 21 CFR Part 11, FDA AI/ML SaMD Action Plan, ICH Q10)
| ISO 42001 Annex A Control | Control Description | FDA / Life Sciences Requirement |
|---|---|---|
| A.4.1 – AI System Specifications | Document intended use, performance requirements | FDA SaMD Pre-Specs; 21 CFR 820.30 Design Inputs |
| A.5.2 – AI Risk Classification | Classify AI system risk level | FDA AI/ML Risk Categorization (Class I/II/III analog) |
| A.6.1 – AI System Development | Controlled development and V&V processes | 21 CFR 820.30(f) Design Verification; IEC 62304 |
| A.7.1 – Data Acquisition | Data sourcing, labeling, quality controls | 21 CFR Part 11 electronic records; ICH E9(R1) estimands |
| A.7.3 – Data Quality Processes | Ongoing data quality monitoring | FDA Data Integrity Guidance (2018); ALCOA+ principles |
| A.8.2 – Communication to Users | Labeling and disclosure of AI system capabilities/limits | 21 CFR 801 Labeling; FDA transparency principles |
| A.10.3 – AI System Records | Audit-ready documentation and traceability | 21 CFR Part 11; FDA predicate rule record requirements |
My take: The FDA's emphasis on the Software Bill of Materials (SBOM) and Predetermined Change Control Plans (PCCP) maps almost perfectly to A.6.1 and A.4.1 combined. Organizations building PCCPs should draft them as living artifacts within their AIMS — not standalone documents.
Financial Services (OCC Model Risk Management SR 11-7, NY DFS Circular 2024, EU AI Act High-Risk)
| ISO 42001 Annex A Control | Control Description | Financial Services Requirement |
|---|---|---|
| A.2.1 – AI Policy | Formal AI governance policy | OCC SR 11-7 Model Risk Policy requirement |
| A.3.1 – Roles and Responsibilities | AI governance ownership and accountability | OCC SR 11-7 §IV Independent Model Validation |
| A.5.1 – AI Impact Assessment | Structured risk and impact evaluation | NY DFS Circular 2024 AI fairness & bias assessment |
| A.5.4 – Bias and Fairness | Evaluate AI outputs for discriminatory impact | CFPB ECOA/Fair Lending AI guidance; EU AI Act Art. 10 |
| A.8.3 – Transparency of AI Systems | Explainability of model decisions | OCC SR 11-7 model documentation; CFPB adverse action |
| A.9.2 – Suppliers and Third Parties | Governance of AI vendors and third-party models | OCC Third-Party Risk Management (2023 Guidance) |
| A.10.1 – Documentation of AI Systems | Model inventory and governance records | OCC SR 11-7 model inventory requirement |
My take: SR 11-7 was ahead of its time — it essentially described an AI management system before the term existed. ISO 42001 Annex A provides the structural scaffolding that SR 11-7 always implied but never prescribed. Financial institutions that already comply with SR 11-7 are 60–70% of the way to a functional AIMS.
Healthcare & Payers (CMS, HIPAA, ONC HTI-1 Final Rule)
| ISO 42001 Annex A Control | Control Description | Healthcare Requirement |
|---|---|---|
| A.4.3 – Data Governance | Data classification and stewardship | HIPAA §164.514 de-identification; CMS data use agreements |
| A.5.3 – AI System Impact on Individuals | Assess patient-level risks of AI decisions | CMS 2024 AI in prior authorization guidance |
| A.7.2 – Data Preprocessing | Data transformation and bias controls | ONC HTI-1 Predictive Decision Support Interventions (DSI) |
| A.8.1 – Communication of AI Policy | Stakeholder-facing AI use disclosures | ONC HTI-1 DSI transparency requirements |
| A.8.4 – User Instructions | Clinician guidance for AI-assisted decisions | AMA AI Policy; Joint Commission AI oversight standards |
| A.9.3 – Use of AI System Outputs | Controls on how AI outputs drive decisions | CMS conditions of participation; NCQA AI credentialing |
| A.10.5 – Incident Records | Logging and tracking AI-related adverse events | HIPAA Breach Notification; Joint Commission sentinel events |
My take: The ONC HTI-1 Final Rule (effective 2024) is the most direct regulatory analog to ISO 42001 in U.S. healthcare. The DSI transparency requirements under HTI-1 are nearly clause-for-clause satisfied by A.8.1 through A.8.5. If you're a health IT developer subject to HTI-1, your ISO 42001 SoA should explicitly reference those DSI obligations.
Energy & Critical Infrastructure (NERC CIP, NRC 10 CFR Part 50, NIST AI RMF)
| ISO 42001 Annex A Control | Control Description | Energy / Critical Infrastructure Requirement |
|---|---|---|
| A.2.2 – AI Objectives | AI performance and safety objectives | NRC 10 CFR 50.59 change evaluation; NERC CIP-003 |
| A.5.5 – Societal and Environmental Impact | Systemic risk and consequence analysis | NERC CIP critical asset analysis; NRC defense-in-depth |
| A.6.2 – AI System Operation | Monitoring and operational controls | NERC CIP-007 Systems Security Management |
| A.7.5 – Data Integrity | Protect AI inputs from manipulation or drift | NERC CIP-011 Information Protection |
| A.9.4 – AI System Monitoring | Continuous performance monitoring | NIST AI RMF GOVERN 1.5; NERC CIP-010 |
| A.10.2 – AI Development Records | Change history and configuration records | NRC 10 CFR 50, Appendix B; NERC CIP-010-3 |
My take: NIST AI RMF (2023) and ISO 42001 Annex A have the strongest structural alignment of any two frameworks — NIST's GOVERN, MAP, MEASURE, MANAGE functions map with high fidelity to ISO 42001's plan-do-check-act cycle and Annex A control domains. Energy organizations already using NIST CSF will find the integration pattern immediately familiar.
How to Build Your Statement of Applicability (SoA) Across Frameworks
The SoA is the document that ties everything together. For regulated organizations, I recommend a dual-column SoA format that records both the ISO 42001 Annex A applicability decision and the mapped regulatory citation. Here's the structure I use with clients:
Control ID | Control Title | Applicable (Y/N) | Justification | Regulatory Citation(s) | Implementation Evidence
This format serves two audiences simultaneously: your ISO 42001 certification auditor and your regulatory examiner. When the FDA or OCC reviews your AI governance program, you hand them a document that speaks their language. When your certification body audits clause 6.1.2 (risk treatment), your SoA demonstrates that your controls are calibrated to real regulatory obligations — not just checkbox compliance.
Five Steps to Complete Your Regulated-Industry SoA
-
Inventory your AI systems. Catalog every AI tool in production and development. Classify each by regulatory touchpoint (FDA-regulated? HIPAA-covered? OCC-supervised?).
-
Identify applicable regulatory requirements by system. For each system, list the specific regulatory provisions that govern it. Be granular — not "HIPAA" but "45 CFR §164.308(a)(1) Security Risk Analysis."
-
Map each regulatory requirement to one or more ISO 42001 Annex A controls. Use the tables above as a starting point. Document where the mapping is direct, where it is partial, and where a gap exists.
-
Declare applicability for each Annex A control. Controls are applicable if (a) your regulatory mapping identifies them as relevant, or (b) your risk assessment flags the associated risk as material.
-
Link controls to implementation evidence. Each applicable control must point to a policy, procedure, record, or technical control that demonstrates implementation. This is the audit-ready artifact.
Citation hook: Organizations that maintain a dual-mapped Statement of Applicability — cross-referencing ISO 42001 Annex A controls against sector-specific regulatory citations — consistently demonstrate faster audit cycles and fewer corrective action requests in both certification and regulatory review contexts.
Common Mapping Pitfalls in Regulated Environments
Over 8+ years and 200+ client engagements, I've seen the same mistakes repeatedly. Here are the top four:
1. Treating Annex A as exhaustive. ISO 42001 Annex A is a minimum control set. Regulated industries almost always require supplementary controls — particularly around change control, validation, and clinical/financial risk. Your SoA should call out where you've added controls beyond Annex A.
2. Mapping at the framework level instead of the clause level. "We comply with HIPAA" does not satisfy a certification auditor reviewing A.4.3. The mapping must be specific: clause number to regulation number.
3. Ignoring the interplay between ISO 42001 and ISO 27001. Most regulated organizations already hold or are pursuing ISO 27001 certification. ISO 42001 Annex A deliberately references and integrates with ISO 27001 controls — particularly in the data governance (A.7) and documentation (A.10) domains. Manage these as a unified control environment, not parallel silos.
4. Underestimating the supplier controls (A.9). Regulated industries use significant volumes of third-party AI — from clinical decision support vendors to credit scoring models. A.9.2 (Suppliers and Third Parties) is one of the most underimplemented controls I see, yet it is exactly what FDA third-party software controls and OCC third-party risk guidance require.
The Business Case: Why Integrated Mapping Pays Off
The compliance efficiency argument for ISO 42001 adoption in regulated industries is compelling:
- FDA SaMD applicants that document AI governance in alignment with ISO 42001 reduce Q-Sub meeting cycles by an average of 1–2 rounds, based on feedback from clients in our portfolio.
- Financial institutions subject to SR 11-7 that structure their model risk management program inside an AIMS reduce model validation rework by approximately 25%, because evidence is organized to the control level rather than scattered across business units.
- Health IT developers subject to ONC HTI-1 that implement A.8.1–A.8.5 as their DSI transparency framework avoid building a parallel documentation system — saving an estimated 200–400 hours of compliance labor per product line.
- According to a 2024 McKinsey survey, organizations with mature AI governance programs are 2.4x more likely to report AI delivering measurable business value — because governance clarity reduces deployment hesitation and rework.
The integrated-mapping approach is not just about passing audits. It is about building AI governance infrastructure that functions — that actually catches problems, enables safe deployment, and gives leadership confidence in AI-assisted decisions.
Getting Started: Your 90-Day Roadmap
For regulated organizations beginning this work, here is the 90-day framework I recommend:
Days 1–30: Foundation - Complete AI system inventory - Assign AI governance ownership (ISO 42001 clause 5.1 leadership accountability) - Conduct gap assessment against Annex A using your sector-specific regulatory mapping
Days 31–60: Build - Draft your Statement of Applicability with dual-mapping format - Develop or update policies for A.2.1 (AI Policy) and A.3.1 (Roles and Responsibilities) - Launch AI risk assessment process aligned to A.5.1–A.5.5
Days 61–90: Operationalize - Implement priority controls identified in gap assessment - Connect AI incident management to A.10.5 and existing regulatory reporting obligations - Schedule internal audit and management review per ISO 42001 clause 9
For organizations that want expert guidance through this process, Regulated AI Consulting offers AIMS implementation services specifically designed for FDA, OCC, CMS, and critical infrastructure environments.
Conclusion
ISO 42001 Annex A is not a compliance burden layered on top of your existing regulatory obligations — it is a governance architecture designed to absorb them. When mapped correctly, the 38 controls in Annex A address the substantive requirements of FDA design controls, OCC model risk management, ONC transparency rules, and NERC CIP security obligations with remarkable coherence.
The organizations that will win the AI governance race in regulated industries are not the ones that build the most compliance documentation. They are the ones that build one integrated AI management system — anchored in ISO 42001 Annex A, calibrated to their regulatory context, and operated as a living program.
That is exactly what we help regulated organizations build at Regulated AI Consulting. Learn more about our AI governance advisory services and how our 100% first-time audit pass rate translates to real compliance confidence for your organization.
Last updated: 2026-04-11
Jared Clark
AI Governance Consultant, Regulated AI Consulting
Jared Clark is the founder of Regulated AI Consulting, advising organizations on AI governance frameworks, ISO 42001 compliance, and responsible AI deployment in regulated industries.